Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts


  Free Subscription

Articles published in Postgrad Med

Retrieve available abstracts of 15 articles:
HTML format
Text format

Single Articles

    January 2018
  1. ZHOU J, Zhang Q, Wang Y, Gao P, et al
    The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis.
    Postgrad Med. 2018;130:129-136.
    PubMed     Text format     Abstract available

    November 2017
  2. NELSON JR, True WS, Le V, Mason RP, et al
    Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Postgrad Med. 2017;129:822-827.
    PubMed     Text format     Abstract available

    Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Postgrad Med. 2017;129:801-810.
    PubMed     Text format     Abstract available

    April 2017
  4. UNAL S, Tanriover MD, Ascioglu S, Demirkazik A, et al
    Turkish doctors' cohort: healthy despite low screening.
    Postgrad Med. 2017;129:393-398.
    PubMed     Text format     Abstract available

    March 2017
  5. KARAGOZ A, Onat A, Aydin M, Can G, et al
    Distinction of hypertriglyceridemic waist phenotype from simple abdominal obesity: interaction with sex hormone-binding globulin levels to confer high coronary risk.
    Postgrad Med. 2017;129:288-295.
    PubMed     Text format     Abstract available

    November 2016
  6. KUSHNER PA, Cobble ME
    Hypertriglyceridemia: the importance of identifying patients at risk.
    Postgrad Med. 2016;128:848-858.
    PubMed     Text format     Abstract available

  7. SU BY, Tian CF, Gao BL, Tong YH, et al
    Correlation of the leucocyte count with traditional and non-traditional components of metabolic syndrome.
    Postgrad Med. 2016;128:805-809.
    PubMed     Text format     Abstract available

  8. CRANDELL JR, Tartaglia C, Tartaglia J
    Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
    Postgrad Med. 2016;128:859-864.
    PubMed     Text format     Abstract available

  9. CHEN K, Li P, Li YJ, Li T, et al
    Sex disparity in the association between hypertriglyceridemic waist phenotype and arterial stiffness in Chinese healthy subjects.
    Postgrad Med. 2016;128:783-789.
    PubMed     Text format     Abstract available

    October 2016
  10. SABATINE MS, Underberg JA, Koren M, Baum SJ, et al
    Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice.
    Postgrad Med. 2016;128 Suppl 1:31-9.
    PubMed     Text format     Abstract available

  11. CERRATO P, Mihalovic M
    The 10(th) Annual Cardiometabolic Health Congress General Session Highlights.
    Postgrad Med. 2016;128 Suppl 1:1-10.
    PubMed     Text format    

    May 2016
  12. ANGLADA-MARTINEZ H, Rovira-Illamola M, Martin-Conde M, Sotoca-Momblona JM, et al
    mHealth intervention to improve medication management in chronically ill patients: analysis of the recruitment process.
    Postgrad Med. 2016;128:427-31.
    PubMed     Text format     Abstract available

    June 2015
  13. BINDLISH S, Presswala LS, Schwartz F
    Lipodystrophy: Syndrome of severe insulin resistance.
    Postgrad Med. 2015;127:511-6.
    PubMed     Text format     Abstract available

    March 2015
  14. KOREN MJ, Roth EM, McKenney JM, Gipe D, et al
    Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
    Postgrad Med. 2015;127:125-32.
    PubMed     Text format     Abstract available

    January 2015
  15. KEDIA AW, Lynch E
    Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Postgrad Med. 2015;127:869-73.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.